De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics
| العنوان: | De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics |
|---|---|
| المؤلفون: | B. Bonan, Erwan Fourn, David Zucman, Karine Sejean, Melanie Doisne, Aurelie Chan Hew Wai, Julie Trichereau, C. Majerholc, Jean-Stephane Giraud |
| المصدر: | PLoS ONE, Vol 15, Iss 9, p e0239704 (2020) PLoS ONE |
| بيانات النشر: | Public Library of Science (PLoS), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | RNA viruses, Male, 0301 basic medicine, Pediatrics, Health Care Providers, Pathology and Laboratory Medicine, Geographical locations, chemistry.chemical_compound, 0302 clinical medicine, Immunodeficiency Viruses, Abacavir, Medicine and Health Sciences, Medicine, Public and Occupational Health, Medical Personnel, 030212 general & internal medicine, Multidisciplinary, Antimicrobials, Pharmaceutics, Drugs, Antiretrovirals, Lamivudine, Viral Load, Middle Aged, Antivirals, Vaccination and Immunization, Community hospital, Europe, Professions, Medical Microbiology, Patient Satisfaction, Viral Pathogens, Rilpivirine, Viruses, Practice Guidelines as Topic, Dolutegravir, Female, France, Pathogens, Research Article, Tablets, medicine.drug, Adult, medicine.medical_specialty, Anti-HIV Agents, Science, Immunology, Antiretroviral Therapy, Emtricitabine, Microbiology, 03 medical and health sciences, Antiviral Therapy, Drug Therapy, Acquired immunodeficiency syndrome (AIDS), Cost Savings, Physicians, Microbial Control, Virology, Retroviruses, Drugs, Generic, Humans, European Union, Microbial Pathogens, Aged, Pharmacology, business.industry, Lentivirus, Organisms, Biology and Life Sciences, HIV, medicine.disease, 030112 virology, Drug Utilization, Health Care, Regimen, chemistry, People and Places, Population Groupings, Preventive Medicine, business, Viral Transmission and Infection |
| الوصف: | In developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients' acceptability to switch from a brand single-tablet regimens [abacavir/lamivudine/dolutegravir (Triumeq®) or emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera®)] to a treatment comprising of two pills: one is a fixed-dose generic combination of 2 Nucleoside Analogs and the second tablet is the third antiretroviral. This study was a prospective observational study in a French hospital. During their follow-up, patients on stable single-tablet regimens were made aware of the possible cost-saving. They were questioned about their willingness and barriers accepting the substitution. Participants chose between the two regimens, either to remain on single-tablet regimens or switch to the de-simplified regimen. Six months later, a second survey was given to the patient who chose to de-simplify and HIV viral load was controlled. The study included 98 patients: 60 receiving emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera®) and 38 on abacavir/lamivudine/dolutegravir (Triumeq®). Forty-five patients accepted the de-simplified treatment, 37 refused and 16 were undecided and followed the decision offered by their physician. The main reason for unwillingness to switch is the number of pills (77.3%). In multivariate model analysis, male patients (p = 0.001) who have taken antiretroviral therapy for over 20 years (p = 0.04) and who retrieve their treatment in their community hospital (p = 0.03) are more likely to accept the switch. Fifty-one patients accepted to replace their single-tablet regimens and six months later, the majority was satisfied; only four returned to single-tablet regimens because of suspected side effects. Half of the people living with HIV/AIDS in our cohort accepted to switch from brand single-tablet regimens to a two-tablet regimen containing generic drugs within a process that emphasizes health expenditure savings. |
| تدمد: | 1932-6203 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9885046c35da2f7e85267ec091789709 https://doi.org/10.1371/journal.pone.0239704 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....9885046c35da2f7e85267ec091789709 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|